IP Library Granted Patent US 12,290,529
Granted Patent B2
US 12,290,529 · App. 18/792,849 · Granted May 6, 2025

Methods of administering safe colon cleansing compositions

Inventors: Edmund V. Dennett (Walpole, MA); Mark Cleveland (Norwell, MA); Russell W. Pelham (Duxbury, MA); Matthew Walker (Brighton, MA)
Assignee: Braintree Laboratories, Inc.
A61K31/765A61K9/08A61K33/04A61K47/02A61K47/26A61P1/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,529
App. No.
18/792,849
Granted
May 6, 2025
Kind
B2
Abstract

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

Claims (9)

1. A colon cleansing product comprising:

(a) a first container comprising a first portion of a first dose of a colon cleansing product comprising about 178.7 grams of polyethylene glycol 3350, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, 0.5 grams of sodium chloride;

(b) a second container comprising a second portion of the first dose of a colon cleansing product comprising malic acid and citric acid;

(c) a third container comprising a first portion of a second dose of the colon cleansing product comprising about 178.7 grams of polyethylene glycol 3350, about 7.3 grams of sodium sulfate, about 1.12 grams of potassium chloride, about 0.9 grams of magnesium sulfate, about 0.5 grams of sodium chloride; and

(d) a fourth container comprising a second portion of the second dose of the colon cleansing product comprising malic acid and citric acid,

wherein the colon cleansing product further comprises lemon-lime flavor, sucralose, and neotame; and

wherein the colon cleansing product is formulated so that the combination of the first dose and second dose cleanse a colon of a subject without causing a sodium balance of −50.00 mEq/L or greater in the subject.

2. The colon cleansing product of claim 1 , wherein the second portion of the first dose of the colon cleansing product comprises about 1.43 grams of malic acid and about 1.64 grams of citric acid.

3. The colon cleansing product of claim 2 , wherein the second portion of the second dose of the colon cleansing product comprises about 1.43 grams of malic acid and about 1.64 grams of citric acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2025
From: BRAINTREE LABORATORIES, INC.; SEBELA IRELAND LIMITED
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 073290/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2025
From: DENNETT, EDMUND V.; CLEVELAND, MARK; PELHAM, RUSSELL W.; WALKER, MATTHEW
To: BRAINTREE LABORATORIES, INC.
Reel/Frame 070734/0042 →